An in vivo study on rodent model revealed at least partly that the molecular pathway of inflammatory reactions in the PCOS cases mediated via the JNK signaling pathway and therefore using a JNK inhibitor (SP600125) resulted in a remarkable reduction of inflammatory biomarkers including hyperemia, inflammatory cell infiltration, vascular congestion and consequently reduction of fibrotic states characterized by reduced amount of produced collagen type IV in PCOS positive rats (52). This evidence concerns the gene MAPK8 and polycystic ovary syndrome.